Hib vaccine - sanofi pasteur/BioPort

Drug Profile

Hib vaccine - sanofi pasteur/BioPort

Alternative Names: Haemophilus influenzae vaccine - sanofi pasteur/BioPort; Hin 47; Otitis media vaccine - sanofi pasteur/BioPort

Latest Information Update: 30 Apr 2007

Price : $50

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Otitis media

Most Recent Events

  • 30 Apr 2007 Discontinued - Phase-II for Otitis media in USA (unspecified route)
  • 18 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top